XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.24.3

Note 7 - Intangible Assets | 3 Months Ended
--- | ---
Sep. 30, 2024
Notes to Financial Statements |
Goodwill and Intangible Assets Disclosure [Text Block] | Note 7 - Intangible Assets A summary of the Company’s definite-lived intangible assets as of September 30, 2024, and June 30, 2024, respectively, is as follows:
|  | September 30, 2024 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |  |  | Weighted-Average Remaining Life |
|  | (in thousands) |  |  | (in years) |
Acquired product technology rights |  | $ | 41,268 |  |  | $ | (13,988 | ) |  | $ | 27,280 |  |  |  | 10.5 |
Acquired technology rights |  |  | 30,200 |  |  |  | (6,275 | ) |  |  | 23,925 |  |  |  | 13.5 |
Total intangible assets |  | $ | 71,468 |  |  | $ | (20,263 | ) |  | $ | 51,205 |  |  |  | 11.9 |
|  | June 30, 2024 |
|  | Gross Carrying Amount |  |  | Accumulated Amortization |  |  | Net Carrying Amount |  |  | Weighted-Average Remaining Life |
|  | (in thousands) |  |  | (in years) |
Acquired product technology rights |  | $ | 41,268 |  |  | $ | (13,184 | ) |  | $ | 28,084 |  |  |  | 10.7 |
Acquired technology rights |  |  | 30,200 |  |  |  | (5,831 | ) |  |  | 24,369 |  |  |  | 13.8 |
Total intangible assets |  | $ | 71,468 |  |  | $ | (19,015 | ) |  | $ | 52,453 |  |  |  | 12.0 |
Carrying amounts are net of any impairment charges from prior periods. An intangible asset with zero net carrying amount at the end of a reporting period is not presented in the table of a future reporting period. Certain of the Company’s amortizable intangible assets include renewal options, extending the expected life of the asset. The renewal periods range between approximately 1 to 20 years depending on the license, patent or other agreement. Renewals are accounted for when they are reasonably assured. Intangible assets are amortized using the straight-line method over the estimated useful lives. Amortization expense of intangible assets was $1.2 million and $1.5 million for the three months ended September 30, 2024, and 2023, respectively. The following table summarizes the estimated future amortization expense to be recognized over the next five fiscal years and periods thereafter:
|  | Estimated Future Amortization Expense |
|  | (in thousands) |
2025 (remaining 9 months) |  | $ | 3,742 |
2026 |  |  | 4,989 |
2027 |  |  | 4,989 |
2028 |  |  | 4,989 |
2029 |  |  | 4,989 |
2030 |  |  | 2,847 |
Thereafter |  |  | 24,660 |
Total future amortization expense |  | $ | 51,205 |
Acquired Product Technology Rights The acquired product technology rights are related to the rights to production, supply and distribution agreements of various products pursuant to the acquisitions of the Pediatric Portfolio in November 2019 and the Neos Acquisition in March 2021. ADHD Portfolio As part of the Neos Acquisition, the Company acquired developed product technology for the production and sale of Adzenys and Cotempla. The formulations for the ADHD products are protected by patented technology. The estimated remaining economic life of these proprietary technologies is 14 years. Karbinal The Company acquired and assumed all rights and obligations pursuant to the supply and distribution agreement, as amended, with Tris Pharma, Inc. (“Tris”) for the exclusive rights to commercialize Karbinal in the United States (the “Tris Karbinal Agreement”). The Tris Karbinal Agreement’s initial term terminates in August of 2033, with an optional initial 20-year extension. Poly-Vi-Flor and Tri-Vi-Flor The Company acquired and assumed all rights and obligations pursuant to a supply and license agreement and various assignment and release agreements, including a previously agreed to settlement and license agreements (the “Poly-Tri Agreements”) for the exclusive rights to commercialize Poly-Vi-Flor and Tri-Vi-Flor in the United States. Acquired Technology Rights TRRP Technology As part of the Neos Acquisition, the Company acquired time release resin particle (“TRRP”) proprietary technology, which is a proprietary drug delivery technology protected by the Company as a trade secret that allows the Company to modify the drug release characteristics of each of its respective products. The TRRP technology underlines each of the ADHD Portfolio core products and can potentially be used in future product development initiatives as well.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContent Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration